Airna, a Cambridge, MA-based biotech firm advancing RNA modifying therapeutics to revive the well being of sufferers with uncommon and customary illnesses, closed a $60m financing spherical.
The financing, which introduced the whole Collection A funding to $90m, was led by Forbion with participation from Ono Enterprise Funding, Alexandria Enterprise Investments, and different new traders, in addition to AIRNA’s current syndicate, together with ARCH Enterprise Companions and ND Capital.
The corporate intends to make use of the funds to advance its lead product candidate into medical trials and additional develop its broad pipeline.
Led by Kris Elverum, President and Chief Govt Officer, Airna is pioneering the invention and improvement of RNA modifying therapeutics to rework the lives of sufferers with uncommon and customary illnesses. Its RESTORE+™ platform relies on analysis by tutorial co-founders Thorsten Stafforst (College of Tübingen) and Jin Billy Li (Stanford College), who had been the primary to elucidate a therapeutic method for exact modifying of RNA.
Airna is advancing its first therapeutic program, a best-in-class product candidate to deal with the inherited genetic illness alpha-1 antitrypsin deficiency (AATD), in addition to a pipeline of therapeutic candidates to handle a number of illnesses with excessive unmet want.
The corporate has analysis operations in Tübingen, Germany.
FinSMEs
31/07/2024
